ABOUT US
关于我们
珠海臻谱基因科技有限公司总部坐落在广东省珠海市横琴新区，是北京长城基因科技有限公司、珠海格力创业投资有限公司和珠海臻谱投资中心（有限合伙）共同投资建立的专门从事艾滋病抗体药物研发、制造和销售的生物技术公司，共同打造和引领全球领先的HIV新药研发和产业化。
珠海臻谱基因最重要的创新产品为艾滋病治疗药物HIV-DNS双特异性抗体系列，该药物涵盖全新的设计理念和国际先进的研发水平，使用量仅为同类竞品的千分之一左右，疗效优于同类竞品。HIV-DNS项目由北京长城基因科技有限公司首创研发，无偿转让给珠海臻谱基因进行HIV-DNS产品的临床前、临床研究、上市申报及未来的生产销售。
董事长李磊，是中国科学院大学及中国科学院软件研究所人工智能专业博士生导师，综合信息系统（国家）重点实验室主任，清华大学ITUH-NE中心首席科学家，国家973计划重大专项首席科学家，国家863计划专家组组长，国务院特殊津贴专家。
首席科学家胡显文，多年从事生物制药相关通用技术的研究及复杂蛋白质药物的研发，尤其是哺乳动物细胞高效表达技术，哺乳动物细胞大规模高效培养技术、基因重组人源（化）抗体的表达与生产的研究。他领导开发的国家一类新药——重组人尿激酶原（rhPro-UK，商品名“普佑克”），是“十一五”期间国家“重大新药创制”科技重大专项的标志性成果。公司核心研发团队包括1名博士后，2名博士，以及3名学士，他们都具有多年生物药的研发经验。珠海臻谱基因致力于HIV预防和治疗相关生物药的开发，为国人及世界人民的健康加油护航。珠海臻谱基因科技有限公司北京分公司坐落于北京市丰台区“北京文化创新工厂万开基地”，拥有核心雇员14名。
Zhuhai Genpro Biotech Co., Ltd., headquartered in Hengqin New District, Zhuhai City, Guangdong Province, is a biotechnology company jointly invested by Beijing Great Wall Gene Biotech Co., LTD., Zhuhai Gree Venture Capital Co., LTD., and Zhuhai Genpro Investment Center (Limited partnership), specializing in the research, development, manufacturing and sales of HIV bispecific antibody drugs. Its goal is to jointly create and lead the world's leading HIV new drug development and industrialization.
The most important innovative product of Zhuhai Genpro is the HIV-DNS bispecific antibody cocktail drug for AIDS treatment, which contains innovative design concept and the international advanced research and development level. Its clinical usage is only one thousandth of that of competitive products, and its therapeutic effect is better. The HIV-DNS project was initiated and developed by Beijing Great Wall Gene, and transferred to Zhuhai Genpro for free for pre-clinical research, clinical research and future production and sales.
Li Lei, chairman of the Board, is a doctoral supervisor of artificial intelligence in the University of Chinese Academy of Sciences and Software research institute of Chinese Academy of Sciences, director of the state Key Laboratory of Integrated Information Systems, chief scientist of ITUH-NE Center of Tsinghua University, Chief scientist of major projects under the national “973 Program”, the leader of the national "863 Program" expert group and the expert receiving special subsidies from the State Council.
Hu Xianwen, the chief scientist, has been engaged in the research of general technologies related to biopharmaceuticals and the research and development of complex protein drugs for many years, especially the high-efficiency expression technology in mammalian cells, large-scale high-efficiency culture technology of mammalian cells, as well as the expression and production of gene recombination humanized antibodies. He led the development of the national class I new medicine--“Recombinant Human Prourokinase” (rhpro-UK, trade name "Pu You Ke"), which was the landmark achievement of the national science and technology major project of “Major New drug Innovation and Production” during the 11th Five-Year Plan period.
The company's core research and development team includes 1 postdoctoral, 2 doctoral, and 3 bachelor’s degree holders, all of whom have many years of research and development experience in biopharmaceutics.
Zhuhai Genpro focuses on the prevention and treatment of HIV infection, hoping to better protect the health of Chinese people and people around the world.
Zhuhai Genpro Technology Co., LTD. Beijing branch company is located in Beijing Cultural Innovation workshop Wankai Base, Fengtai District, Beijing, with 14 core employees.
